// App-Quantinova.ai

4624 : Use of Recombinant Factor VIIa (rFVIIa) for Acute Bleeding Episodes in Acquired Hemophilia: Final Analysis From the Hemostasis and Thrombosis Research Society (HTRS) Registry AH Study

Researchers

Presenter

  • Craig M. Kessler

Principal Investigators

  • Hamid A B Al-Mondhiry

  • Margaret Fisher

  • Robert Z. Gut

  • David L. Cooper

Medical Centers

  • Hemophilia Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA,

Locations

  • United States

Companies

  • Novo Nordisk A/S

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Hemophilia

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • rFVIIa

  • FVIII

  • Hemostatic Solution

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved